Search Results 761-770 of 16867 for Amphotericin B

  1. Breast cancer - Doctors and departments - Mayo Clinic

    May Elbanna, M.B., B.Ch., Ph.D. Radiation Oncologist. Rochester, MN. Areas of focus: Radiation therapy, Proton therapy ...

  2. Publications - Bassam G. Abu Jawdeh, M.D. - Mayo Clinic

    Rios IP, Elsaidi A, Akin DE, Nowland AM, Budhiraja P, Hommos MS, Heilman RL, Abu Jawdeh BG. · Khan MA, Mehmood M, El Azzazi H, Shaikh S, Bhasin-Chhabra B, ...

  3. Medical Research & Education - Mayo Clinic News Network

    ... B-. Cancer. Mayo Clinic prepares to biomanufacture a new CAR-T cell therapy for recurring B-cell blood cancers. Susan Buckles. October 10, 2023. Preparing to ...

  4. Arthritis - Doctors and departments - Mayo Clinic

    Anushka Irani, B.M., B.Ch., Ph.D. Rheumatologist. Jacksonville, FL ...

  5. Critical Care - Doctors - Mayo Clinic

    Displaying 1-3 out of 3 doctors available · Arun L. Jayaraman, M.D., Ph.D. · Jeffrey B. Jensen, M.D. · John Joerns, M.D..

  6. Clinical trials - Oncology (Medical)

    The purpose of this study is to provide access to CTL019 through Managed Access Program (MAP) for acute lymphoblastic leukemia (ALL) or diffuse large b-cell ...

  7. Medicine use in older adults - Mayo Clinic

    Long-term use also increases the risk of bone loss, fractures, and vitamin B-12 deficiency. Skeletal muscle relaxants relieve muscle spasms. Most muscle ...

  8. Hematology - Doctors - Mayo Clinic

    Find a doctor whose last name begins with the letter B B · Find a doctor whose ... Urshila Durani, M.D., M.P.H.. Internist; Oncologist; Hematologist. Rochester, ...

  9. An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies - Mayo Clinic

    ... b) subject is intolerant to standard anticancer therapy. Life expectancy > 12 weeks. ECOG performance status: a. Part 1: 0-1. b. Part 2: 0-2. Archival tumor ...

  10. Clinical trials - Oncology (Medical)

    1 cells administered following a conditioning lymphodepletion regimen in diffuse large B cell lymphoma (DLBCL) subjects who failed at least two lines of therapy ...